Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-01-12, Stock:ABBV, The news for the past five days is as follows:
2018-01-05: NEWS1: Why AbbVie Could See a Big Rise in Its Net Profit Margin in Fiscal 2017.NEWS2: Spiros Segalas Buys 3 New Stocks in 4th Quarter.NEWS3: Why AbbVie Is Expected to Report Robust Revenue Growth for 2017.NEWS4: Will J&J (JNJ) Continue to Tread Growth Path This Year?.NEWS5: AbbVie and Peers: Analyst Recommendations in December.NEWS6: Key Biosimilar Approvals in 2017: Progress Report.NEWS7: Biotech: The Tide Is Turning.NEWS8: Will J&J (JNJ) Continue to Tread Growth Path This Year?.NEWS9: Key Biosimilar Approvals in 2017: Progress Report.NEWS10: 3 Large-Cap Pharma Stocks to Watch Out for This New Year.
2018-01-08: NEWS1: Cramer&apos;s lightning round: Mercadolibre is even better than eBay was.NEWS2: Cramer's lightning round: Mercadolibre is even better than eBay was.NEWS3: Galapagos Reports Topline Data From Osteoarthritis Study.NEWS4: Understanding AbbVie’s Positive Upadacitinib Data for Atopic Dermatitis.NEWS5: US STOCKS-Wall St new year rally pauses as healthcare, bank stocks weigh.NEWS6: Galapagos Reports Topline Data From Osteoarthritis Study.NEWS7: Why AbbVie’s Upadacitinib Keeps Posting Strong Data for Rheumatoid Arthritis.NEWS8: AbbVie's Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis.NEWS9: What Upadacitinib Did for AbbVie in 2017.NEWS10: This Is Expected to Boost AbbVie’s Growth Prospects.NEWS11: Why Humira Is Still a Solid Growth Driver for AbbVie in 2018.NEWS12: How Increasing Biologic Penetration Could Boost AbbVie’s Revenues.
2018-01-09: NEWS1: AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio.NEWS2: 5 Ways Gilead Sciences Plans to Return to Growth.NEWS3: Notable Tuesday Option Activity: MCK, ABBV, BIIB.NEWS4: AbbVie&apos;s Upadacitinib Gains Breakthrough Therapy Designation.NEWS5: Is AbbVie Stock Still A Strong Buy?.NEWS6: AbbVie’s Venclexta for Chronic Lymphocytic Leukemia.NEWS7: AbbVie Expects Peak Sales of $7 Billion for Imbruvica.NEWS8: 4 Best Marijuana Stocks to Play the Green Rush.NEWS9: Is AbbVie Stock Still A Strong Buy?.NEWS10: 4 Best Marijuana Stocks to Play the Green Rush.NEWS11: AbbVie"s JAK1 Inhibitor Granted FDA"s Breakthrough Therapy.NEWS12: Ex-Dividend Reminder: Patterson Companies, AbbVie and Abbott Laboratories.NEWS13: Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications.NEWS14: See what the IHS Markit Score report has to say about AbbVie Inc..NEWS15: Cramer's lightning round: Mercadolibre is even better tha....
2018-01-10: NEWS1: Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar.NEWS2: AbbVie’s Rova-T: Can Label Expansion Make It a Blockbuster Drug?.NEWS3: Analysts’ Recommendations for Incyte in January 2018.NEWS4: Novartis Starts Trial on Psoriasis Drug Cosentyx Biosoimilar.NEWS5: AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for January 11, 2018.NEWS6: Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus.NEWS7: AbbVie’s Rova-T and the Treatment of Small Cell Lung Cancer.NEWS8: Why AbbVie Wants Imbruvica to Be a Foundation Therapy in Hematologic Oncology.NEWS9: Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ).NEWS10: AbbVie’s Rova-T: Solid Growth Driver for the Future?.NEWS11: AbbVie’s Position in the Growing Oncology Market in 2018.NEWS12: Ex-Dividend Alert: AbbVie Raised its Dividend by 11%; Will Trade Ex-Dividend on January 11, 2018.NEWS13: Better Stock: AbbVie Inc (ABBV) vs. Johnson & Johnson (JNJ).NEWS14: LPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 Again.NEWS15: LPCN Awaits FDA Panel Vote Today, APHB Slumps, BGNE Crosses $100 Again.NEWS16: AbbVie's Upadacitinib Gains Breakthrough Therapy Designation.
2018-01-11: NEWS1: Why TG Therapeutics Rallied 15.7% Today.NEWS2: Jeff Sessions is Taking Some Steam Out of the Marijuana Stocks Rally.NEWS3: Earnings Season Watch List: AbbVie.NEWS4: FDA Advisers Slam Lipocine's Testosterone Pill, Raising Doubts About 'Low T' Drugs.NEWS5: Mavyret May Prove a Strong Growth Driver for AbbVie Going Forward.NEWS6: Elagolix May Advance the Treatment Paradigm in Women’s Health.NEWS7: Jeff Sessions is Taking Some Steam Out of the Marijuana Stocks Rally.NEWS8: Here's What AbbVie's Management Just Said About Its Future.NEWS9: Miles White's Bold Moves Made Abbott Laboratories A Global Force.NEWS10: 7 Must-See Numbers from AbbVie's J. P. Morgan Presentation.NEWS11: Here&apos;s What AbbVie&apos;s Management Just Said About Its Future.NEWS12: How Ionis’s Spinraza Performed in 3Q17.NEWS13: Miles White&apos;s Bold Moves Made Abbott Laboratories A Global Force.NEWS14: 7 Must-See Numbers From AbbVie&apos;s J. P. Morgan Presentation.NEWS15: Earnings Season Watch List: AbbVie.

Answer: Rise